Abstract:BACKGROUND:Efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor (NNRTI), has been widely used in the therapy of human immunodeficiency virus (HIV) infection. Some of its toxic effects on hepatic cells have been reported to display features of mitochondrial dysfunction through bioenergetic stress and autophagy, etc. However, alteration of protein levels, especially mitochondrial protein levels, in hepatic cells during treatment of EFV has not been fully investigated.METHODS:We built a cell model of EFV-induced liver toxicity through treating Huh-7 cells with different concentrations of EFV for different time followed by the analysis of cell viability using cell counting kit -8 (CCK8) and reactive oxygen species (ROS) using 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) and MitoSox dye. Proteomic profiles in the mitochondria of Huh-7 cells stimulated by EFV were analyzed. Four differentially expressed proteins were quantified by real time RT-PCR. We also detected the expression of mitochondrial precursor Cob(I)yrinic acid a,c-diamide adenosyltransferase (MMAB) by immunohistochemistry analysis in clinical samples. The expression levels of MMAB and ROS were detected in EFV-treated Huh-7 cells with and without shRNA used to knock down MMAB, and in primary hepatocytes (PHC). The effects of other anti-HIV drugs (nevirapine (NVP) and tenofovirdisoproxil (TDF)), and hydrogen peroxide (H2O2) were also tested. Amino acid analysis and fatty aldehyde dehydrogenase (ALDH3A2) expression after MMAB expression knock-down with shRNA was used to investigate the metabolic effect of MMAB in Huh-7 cells.RESULTS:EFV treatment inhibited cell viability and increased ROS production with time- and concentration-dependence. Proteomic study was performed at 2 hours after EFV treatment. After treated Huh-7 cells with EFV (2.5mg/L or 10 mg/L) for 2 h, fifteen differentially expressed protein spots from purified mitochondrion that included four mitochondria proteins were detected in EFV-treated Huh-7 cells compared to controls. Consistent with protein expression levels, mRNA expression levels of mitochondrial protein MMAB were also increased by EFV treatment. In addition, the liver of EFV-treated HIV infected patients showed substantially higher levels of MMAB expression compared to the livers of untreated or protease inhibitor (PI)-treated HIV-infected patients. Furthermore, ROS were found to be decreased in Huh-7 cells treated with shMMAB compared with empty plasmid treated with EFV at the concentration of 2.5 or 10 mg/L. MMAB was increased in EFV-treated Huh-7 cells and primary hepatocytes. However, no change in MMAB expression was detected after treatment of Huh-7 cells and primary hepatocytes with anti-HIV drugs nevirapine (NVP) and tenofovirdisoproxil (TDF), or hydrogen peroxide (H2O2), although ROS was increased in these cells. Finally, knockdown of MMAB by shRNA induced increases in the β-Alanine (β-Ala) production levels and decrease in ALDH3A2 expression.CONCLUSIONS:A mitochondrial proteomic study was performed to study the proteins related to EFV-inducted liver toxicity. MMAB might be a target and potential biomarker of hepatotoxicity in EFV-induced liver toxicity.

[Assessment of Mitochondrial Toxicity Induced by Zidovudine and Adefovir Dipivoxil in Rats].

Dysregulation of autophagy in rat liver with mitochondrial DNA depletion induced by the nucleoside analogue zidovudine

In Vivo Assessment of Mitochondrial Toxicity of Metacavir in Rhesus Monkeys after Three Months of Intravenous Administration

Protective effect of histone deacetylase inhibitor ACY1215 on hepatocyte mitochondria in rats with acute hepatic failure

' s response to reviews Title : Voltage-dependent anion channel is involved in the apoptosis of cell lines carrying mitochondrial DNA A 4263 G mutation

Mitochondrial toxicities of nucleoside analogue reverse transcriptase inhibitors in AIDS cases

Increased MMAB Level in Mitochondria As a Novel Biomarker of Hepatotoxicity Induced by Efavirenz

Resveratrol Attenuates Azidothymidine-Induced Cardiotoxicity by Decreasing Mitochondrial Reactive Oxygen Species Generation in Human Cardiomyocytes.

Early Kidney Injury During Long-Term Adefovir Dipivoxil Therapy for Chronic Hepatitis B.

In Vitro Mitochondrial Toxicity Of Metacavir, A New Nucleoside Reverse Transcriptase Inhibitor For Treatment Of Hepatitis B Virus

Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage

Acute Liver Failure Enhances Oral Plasma Exposure of Zidovudine in Rats by Downregulation of Hepatic UGT2B7 and Intestinal P-gp

Mitochondrial Toxicogenomics for Antiretroviral Management: HIV Post-exposure Prophylaxis in Uninfected Patients

Evaluation of mitochondrial toxicity in Marmota himalayana treated with metacavir, a novel 2',3'-dideoxyguanosine prodrug for treatment of hepatitis B Virus.

Uridine Abrogates the Adverse Effects of Antiretroviral Pyrimidine Analogues on Adipose Cell Functions

Mitochondrial Toxicity Of Tenofovir Dipivoxil Fumaratein Hk-2 Cells

Tenofovir and adefovir down-regulate mitochondrial chaperone TRAP1 and succinate dehydrogenase subunit B to metabolically reprogram glucose metabolism and induce nephrotoxicity

Aloe-emodin relieves zidovudine-induced injury in neonatal rat ventricular myocytes by regulating the p90rsk/p-bad/bcl-2 signaling pathway

Mitochondrial toxicity mechanism of nucleoside analogues and its clinical manifestations

Combination and Monotherapy with Zidovudine and Zalcitabine in Patients with Advanced HIV Disease

Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss